Literature DB >> 7140977

Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide.

D Bataille, K Tatemoto, C Gespach, H Jörnvall, G Rosselin, V Mutt.   

Abstract

A peptide isolated from porcine gut according to its glucagon-like activity in liver (bioactive enteroglucagon) has been characterized immunologically, biologically and chemically: its potency relative to pancreatic glucagon in interacting with an antiglucagon antibody, hepatic glucagon-binding sites and hepatic adenylate cyclase was approximately 100%, 20% and 10%, respectively. In contrast, it is approximately 20-times more potent than glucagon in oxyntic glands, justifying the term 'oxyntomodulin'. Chemically, it consists in the 29 amino acid-peptide glucagon elongated at its C-terminal end by the octapeptide Lys-Arg-Asn-Lys-Asn-Asn-Ile-Ala; accordingly, it is called 'glucagon-37'.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7140977     DOI: 10.1016/0014-5793(82)80709-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

Review 1.  Bowels control brain: gut hormones and obesity.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 3.  Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Authors:  Benjamin C T Field; Alison M Wren; Dunstan Cooke; Stephen R Bloom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 5.  Therapy for obesity based on gastrointestinal hormones.

Authors:  Jonatan I Bagger; Mikkel Christensen; Filip K Knop; Tina Vilsbøll
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 6.  Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones.

Authors:  Amosy E M'Koma; Paul E Wise; Roberta L Muldoon; David A Schwartz; Mary K Washington; Alan J Herline
Journal:  Int J Colorectal Dis       Date:  2007-06-19       Impact factor: 2.571

7.  Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas.

Authors:  A Ali-Rachedi; I M Varndell; T E Adrian; D A Gapp; S Van Noorden; S R Bloom; J M Polak
Journal:  Histochemistry       Date:  1984

8.  Selective disappearance of histamine H2-receptor activity in the human gastric cancer cell line HGT-1 after short-term or chronic treatment by histamine or its H2-antagonists.

Authors:  S Emami; C Gespach; H Bodéré
Journal:  Agents Actions       Date:  1985-04

9.  Circulating glucagon after total pancreatectomy in man.

Authors:  J J Holst; J H Pedersen; F Baldissera; F Stadil
Journal:  Diabetologia       Date:  1983-11       Impact factor: 10.122

10.  N-acetyl oxyntomodulin30-37: pharmacokinetics and activity on gastric acid secretion.

Authors:  C Carles-Bonnet; C Jarrousse; H Niel; J Martinez; M Rolland; D Bataille
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-01       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.